Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech News -- Ignore unavailable to you. Want to Upgrade?

To: Gary Mohilner who wrote (6302)	8/16/2008 7:48:17 AM
From: Biotech Jim	Read Replies (2) \| Respond to of 7143

I generally agree with your view about Dr. initiated experimentation/testing in patients, but that is a very slippery slope... The double edged sword of efficacy vs safety of course is the issue in this litigious society. Beyond that how does one prove efficacy in specialized situations of polypharmacy to convincingly show utility. These are not simple issues. Regarding salaries, sure things are out of whack. What do you think of the situation where CEOs do not get a salary, but take their "pay" only in options, like for instance Kelly Martin at ELN? I think big pharma is trimming the numbers of execs and multiple managers (g), but unfortunately the execs may cut researchers before themselves in restructurings. But I caution myself in painting the industry with a single brush. BJ